Skip to main content
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

  • Register
  • Log in
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in

Search

  • Advanced search
Cancer Research
Cancer Research

Advanced Search

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
Experimental and Molecular Therapeutics

Abstract 752: In vivo pharmaceutical targets screening using lentiviral inducible-knockdown shRNA system

Yinfei Yin, Richard H. Argent, Rajendra Kumari, Susan A. Watson, Peter King, Brett M. Hall and Anna M. Grabowska
Yinfei Yin
1University of Nottingham, Nottingham, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Richard H. Argent
1University of Nottingham, Nottingham, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rajendra Kumari
1University of Nottingham, Nottingham, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Susan A. Watson
1University of Nottingham, Nottingham, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter King
2OrthoBiotech Oncology Research & Development, a Division of Johnson & Johnson Pharmaceuticals, Beerse, Belgium.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Brett M. Hall
2OrthoBiotech Oncology Research & Development, a Division of Johnson & Johnson Pharmaceuticals, Beerse, Belgium.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anna M. Grabowska
1University of Nottingham, Nottingham, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1538-7445.AM10-752 Published April 2010
  • Article
  • Info & Metrics
Loading
Proceedings: AACR 101st Annual Meeting 2010‐‐ Apr 17‐21, 2010; Washington, DC

Abstract

Background and Aims: Small interfering RNAs (shRNAs) are able to suppress gene expression through the endogenous cellular process of RNA interference pathway. Given the ability to knock-down essentially any gene, shRNAs have been used in many studies to screen for therapeutic targets in various pathological conditions. However, most of these studies have been carried out in vitro and the results cannot always be translated into an in vivo environment. In this project, we aimed to develop an efficient in vivo cancer target validation method using a lentiviral inducible-knockdown shRNA. To verify our approach, we used an essential cell-cycle protein polo-like kinase 1 (PLK1) as a proof of concept target.

Methods: TRIPZ inducible shRNAmir construct (Open Biosystems) carrying shRNA against PLK1 was transfected into the colon carcinoma cell line SW620 using lentiviral transduction. PLK1 gene knock-down following induction with doxycycline was quantified by real-time PCR. Inducible shRNAmir expression (detected by turboRFP) was monitored by fluorescence microscopy and quantified using Flow-cytometry or a fluorescence microplate reader.

Nude mouse xenografts were established by subcutaneous injection of 5×106 PLK1 shRNA transfected SW620 cells into the left flank of female nude mice. Doxycycline treatment (80mg/kilogram daily via oral gavage) was initiated when the mean tumour volume reached 500mm3. Mice were sacrificed 3 weeks following treatment and tumours were collected. PLK1 gene expression was assessed by RT-PCR and protein levels investigated using immunohistochemistry. Assessment of angiogenesis (micro-vessel density) was carried out using CD34 staining.

Results:

Following doxycycline induction in vitro, PLK1 inducible-knockdown SW620 cells showed dose and time-dependent PLK1 down-regulation, which was consistent with shRNAmir expression as marked by turboRFP. Flow-cytometry analysis showed about 95% of cells expressed the shRNAmir, 72 hours after induction.

In the in vivo model, the doxycycline-treated group showed significantly lower PLK1 gene expression compared with untreated control (60% reduction, p<0.003). The doxycycline-treated group also showed significantly lower PLK1 protein expression compared with the untreated control (p<0.001).

There was a decline in tumour growth rate in the treated group compared with the control group, which confirmed that knock-down of PLK1 slowed down tumour growth.

We also observed that, within the tumours from the doxycycline-treated group, there appeared to be reduced PLK1 expression in areas adjacent to the blood vessels compared with other areas of the tumour.

Conclusion: The results support the anti-tumour effects of PLK1 down-regulation and confirm an efficient methodology for cancer target screening using a lentiviral inducible-knockdown shRNA system.

Note: This abstract was not presented at the AACR 101st Annual Meeting 2010 because the presenter was unable to attend.

Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 752.

  • ©2010 American Association for Cancer Research
Back to top
Cancer Research: 70 (8 Supplement)
April 2010
Volume 70, Issue 8 Supplement
  • Table of Contents
  • Index by Author

Sign up for alerts

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Abstract 752: In vivo pharmaceutical targets screening using lentiviral inducible-knockdown shRNA system
(Your Name) has forwarded a page to you from Cancer Research
(Your Name) thought you would be interested in this article in Cancer Research.
Citation Tools
Abstract 752: In vivo pharmaceutical targets screening using lentiviral inducible-knockdown shRNA system
Yinfei Yin, Richard H. Argent, Rajendra Kumari, Susan A. Watson, Peter King, Brett M. Hall and Anna M. Grabowska
Cancer Res April 15 2010 (70) (8 Supplement) 752; DOI: 10.1158/1538-7445.AM10-752

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Abstract 752: In vivo pharmaceutical targets screening using lentiviral inducible-knockdown shRNA system
Yinfei Yin, Richard H. Argent, Rajendra Kumari, Susan A. Watson, Peter King, Brett M. Hall and Anna M. Grabowska
Cancer Res April 15 2010 (70) (8 Supplement) 752; DOI: 10.1158/1538-7445.AM10-752
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

Experimental and Molecular Therapeutics

  • Abstract SY14-03: Anaplastic lymphoma kinase (ALK): Normal biology and role in hematopoietic malignancies
  • Abstract SY18-01: Targeting the p53-MDM2 interaction for cancer therapy
  • Abstract SSY01-04: Discovery and validation of genome-wide genetic signatures of chemotherapy susceptibility: A translational model
Show more 3

Poster Presentations - Proffered Abstracts

  • Abstract LB-236: Risk of tMDS/AML after chemotherapy for first primary lymphoid malignancy, 2000-2013
  • Abstract LB-001: Impact of direct physician engagement with racial/ethnic minorities for oncology clinical trial access and accrual model
  • Abstract LB-107: EV-TRACK: transparent reporting and centralizing knowledge of extracellular vesicles to support the validation of extracellular vesicle biomarkers in cancer research
Show more 3

Poster Presentations - Drug Design and Target Validation

  • Abstract 744: Determining the mechanism of action of novel bisintercalating agents using the cDNA microarray technology
  • Abstract 751: Synthesis of irofulven analogs
  • Abstract 724: Selective β2-adrenergic receptor agonists inhibit the proliferation of 1321N1 astrocytoma cells
Show more 3
  • Home
  • Alerts
  • Feedback
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians
  • Reviewers

About Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2018 by the American Association for Cancer Research.

Cancer Research Online ISSN: 1538-7445
Cancer Research Print ISSN: 0008-5472
Journal of Cancer Research ISSN: 0099-7013
American Journal of Cancer ISSN: 0099-7374

Advertisement